TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7971537

Group type: EXPERIMENTAL
Intervention: Short advice by the physician (I)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Lengthy advice by the physician (III)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patient-centred discussion (IV)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Short question by the patient (II)
Number of subjects: 46
Study: 3687203

Group type: EXPERIMENTAL
Intervention: Intervention goals related to changing cardiovascular risk factors, morbidity, and subjective health
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Psychosocial and somatic factors
Number of subjects: 620
Study: 29175541

Group type: EXPERIMENTAL
Intervention: Cough stress test with bladder filled to half functional capacity
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cough stress tests (various positions and bladder volumes)
Number of subjects: 140

Group type: COMPARATOR
Intervention: 24-hour pad test
Number of subjects: 140
Study: 27553205

Group type: EXPERIMENTAL
Intervention: Split-dose 2L-PEGA
Number of subjects: 198

Group type: COMPARATOR
Intervention: Single-dose 4L-PEG
Number of subjects: 198

Group type: COMPARATOR
Intervention: Split-dose 4L-PEG
Number of subjects: 198
Study: 24105362

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention
Number of subjects: 31
Study: 23376362

Group type: EXPERIMENTAL
Intervention: Peginterferon (PegIFN) therapy for 52 weeks
Number of subjects: 210
Study: 19963403

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (ARTZ Dispo) 25 mg/wk for 5 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (ARTZ Dispo)
Number of subjects: 51
Study: 18280580

Group type: EXPERIMENTAL
Intervention: Somatic Symptoms Inventory (SSI) assessment in patients with MDD
Number of subjects: 2191

Group type: EXPERIMENTAL
Intervention: Correlation with Hamilton Depression Rating Scale (HAMD)
Number of subjects: 2191
Study: 16905181

Group type: COMPARATOR
Intervention: High-risk cardiovascular prevention approach including complete registration of risk factors, optimization of medical treatment, and health counseling on high fat consumption, smoking, and physical inactivity.
Number of subjects: 1300

Group type: COMPARATOR
Intervention: High-risk cardiovascular prevention approach
Number of subjects: 1300
Study: 12815565

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5010
Study: 10657828

Group type: EXPERIMENTAL
Intervention: AS-3 red blood cells stored for ≤42 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Citrate, phosphate, dextrose, and adenine RBCs stored for ≤7 days
Number of subjects: 54
Study: 9357453

Group type: EXPERIMENTAL
Intervention: Vein cuff
Number of subjects: 261

Group type: COMPARATOR
Intervention: No vein cuff
Number of subjects: 261
Study: 8460758

Group type: EXPERIMENTAL
Intervention: Morphine at 1 mg.h-1 combined with ketamine at 5 mg.h-1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Morphine at 1 mg.h-1 combined with ketamine at 10 mg.h-1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Morphine at 1 mg.h-1 combined with ketamine at 20 mg.h-1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine at 1 mg.h-1 alone
Number of subjects: 40
Study: 3536521

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: methysergide (M)
Number of subjects: 124
Study: 31902378

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids from flaxseed oil (2 × 1000 mg/d, containing 400 mg α-linolenic acid per capsule)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids from flaxseed oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30998063

Group type: EXPERIMENTAL
Intervention: Coping skills training (CST)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usual care enhanced by HF education (HFE)
Number of subjects: 179
Study: 27825572

Group type: EXPERIMENTAL
Intervention: Ice (30min, applied twice at 8h interval)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cold CO2 (2min, applied twice at 8h interval)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral non-treated knees (control group)
Number of subjects: 30
Study: 26000667

Group type: EXPERIMENTAL
Intervention: 8 mL of 0.5% lidocaine (group L)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 6 mL of 0.5% lidocaine mixed with 80 mg (2 mL) of methylprednisolone acetate (group LS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Both groups (L and LS)
Number of subjects: 69
Study: 23433200

Group type: EXPERIMENTAL
Intervention: Probiotic compound (seven bacterial species including Lactobacillus and Bifidobacterium strains and Streptococcus thermophiles)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Probiotic compound
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Probiotic compound and Placebo
Number of subjects: 180
Study: 21840828

Group type: EXPERIMENTAL
Intervention: Highly Purified Follicle Stimulating Hormone (HP-FSH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant Follicle Stimulating Hormone (rFSH)
Number of subjects: 0
Study: 19847725

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural depression management training
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard rehabilitation without management of depressive symptoms
Number of subjects: 75
Study: 16696861

Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional unilateral transflaval discectomy
Number of subjects: 0
Study: 14706955

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 87
Study: 11231765

Group type: EXPERIMENTAL
Intervention: Ocular hypertension patients
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 55
Study: 10095928

Group type: EXPERIMENTAL
Intervention: Escherichia coli resistant to antibiotics
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Escherichia coli resistant to various antibiotics
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Escherichia coli resistant to gentamicin, streptomycin, chloramphenicol, tetracycline, trimethoprim, and sulfamethoxazole
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Escherichia coli resistant to ampicillin, piperacillin, amikacin, streptomycin, chloramphenicol, tetracycline, trimethoprim, and sulfamethoxazole
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Escherichia coli resistant to five or more antibiotics
Number of subjects: 100
Study: 8001628

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14621746

Group type: EXPERIMENTAL
Intervention: PGE1 (40 microg/kg twice a day, intravenously from day 1 to day 7)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no PGE1)
Number of subjects: 45
Study: 414280

Group type: EXPERIMENTAL
Intervention: L-Dopa (1.5 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminophylline (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminophylline (200 mg) plus Ephedrine (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30304481

Group type: EXPERIMENTAL
Intervention: PlateDesigner web-based application for randomization in microplate experiments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PlateDesigner web-based application
Number of subjects: 0
Study: 28679605

Group type: EXPERIMENTAL
Intervention: Nocturnal noninvasive ventilation (NIV) for three additional nights (n=61)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Direct NIV discontinuation (n=59)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nocturnal NIV for three additional nights (n=61)
Number of subjects: 120
Study: 26118825

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every-other-week
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg every-other-week
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Dose escalation to 80 mg every-other-week for patients with suboptimal response to 40 mg
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Adalimumab (both doses)
Number of subjects: 147
Study: 23865389

Group type: EXPERIMENTAL
Intervention: Higher HbA1c concentration
Number of subjects: 2270

Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 2270

Group type: EXPERIMENTAL
Intervention: Increase in HbA1c of one percentage point
Number of subjects: 2270

Group type: EXPERIMENTAL
Intervention: HbA1c of 37 mmol/mol (5.5%)
Number of subjects: 2270
Study: 21717822

Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/day for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 19400885

Group type: EXPERIMENTAL
Intervention: 20% salicylic acid peels followed by three 30% salicylic acid peels
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (untreated half of the face)
Number of subjects: 10
Study: 16766971

Group type: EXPERIMENTAL
Intervention: Active ITD (‐7 cmH2O)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham ITD (0 cmH2O)
Number of subjects: 8
Study: 15867711

Group type: EXPERIMENTAL
Intervention: Reusable absorbent body-worn products (Paddy T)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Disposable all-in-one product
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Reusable products (other than Paddy T)
Number of subjects: 14
Study: 11166969

Group type: EXPERIMENTAL
Intervention: MST (oral retarded morphine sulphate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 12
Study: 9731991

Group type: EXPERIMENTAL
Intervention: Lansoprazole in combination with antibiotics (amoxicillin, clarithromycin, metronidazole, or tinidazole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple therapy including lansoprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lansoprazole vs. other PPIs (e.g., omeprazole)
Number of subjects: 0
Study: 7987362

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (4 g/day for 14 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control I (CON I, Day 0)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control II (CON II, Day 14)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-carnitine (L-CN, Day 28)
Number of subjects: 8
Study: 2660640

Group type: EXPERIMENTAL
Intervention: Nalbuphine (15 micrograms.kg‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pentazocine (45 micrograms.kg‐1)
Number of subjects: 40
Study: 31162757

Group type: EXPERIMENTAL
Intervention: Bladder training (clamping urinary catheters at 4-hr intervals and leaving them open for 5 min on the second postoperative day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 50
Study: 31633844

Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamycin
Number of subjects: 7169

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 7169

Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam plus amoxicillin-clavulanic acid
Number of subjects: 7169

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 7169

Group type: EXPERIMENTAL
Intervention: Erythromycin plus ampicillin plus amoxicillin
Number of subjects: 7169

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 7169

Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamicin
Number of subjects: 7169
Study: 28789712

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Micronutrient powder (MNP)
Number of subjects: 422
Study: 25105727

Group type: EXPERIMENTAL
Intervention: Short sleep (5 hr time in bed)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Long sleep (9 hr time in bed)
Number of subjects: 12
Study: 23782590

Group type: EXPERIMENTAL
Intervention: TAU + SWT (Treatment As Usual + Structured Writing Therapy)
Number of subjects: 34

Group type: COMPARATOR
Intervention: TAU (Treatment As Usual)
Number of subjects: 34
Study: 20479668

Group type: EXPERIMENTAL
Intervention: Oral gabapentin 900 mg plus normal saline infiltration (G)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oral gabapentin 900 mg plus 2% lidocaine infiltration (GL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Oral placebo plus 2% lidocaine infiltration (L)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oral gabapentin 900 mg (G)
Number of subjects: 43
Study: 18462650

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 137

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 137
Study: 16986593

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 14656787

Group type: EXPERIMENTAL
Intervention: Face mask at 5 L*min(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mike Cannula at 5 L*min(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OxyArm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 0
Study: 11448573

Group type: EXPERIMENTAL
Intervention: CR (20.0 g of CR/d for 7 d followed by 10.0 g of CR/d for 14 d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HMB (3.0 g of HMB/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CR/HMB (CR and HMB combined)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9756248

Group type: EXPERIMENTAL
Intervention: dexamfenfluramine (d‐fen)
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 7804510

Group type: EXPERIMENTAL
Intervention: Urapidil (U) - bolus of 25 mg; initial infusion rate of 15-85 micrograms/kg/min; maintenance infusion rate of 2-7 micrograms/kg/min
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sodium Nitroprusside (S) - initial infusion rate of 1-2 micrograms/kg/min; maintenance infusion rate of max. 5 micrograms/kg/min
Number of subjects: 53
Study: 2967917

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Captopril (in high-risk subset)
Number of subjects: 59
Study: 30189012

Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone (5/2.5 or 10/5 mg) during haemodialysis
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone (5/2.5 or 10/5 mg) between haemodialysis sessions
Number of subjects: 9
Study: 27973690

Group type: EXPERIMENTAL
Intervention: Immediate loading after implant placement (N = 81, group A)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Delayed loading after three months (N = 77, group B)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Delayed loading protocol
Number of subjects: 158
Study: 26699193

Group type: EXPERIMENTAL
Intervention: Intrauterine pressure (IUP) measured in Montevideo units (MU)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: IUP < 100 MU
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: IUP > 300 MU
Number of subjects: 503

Group type: COMPARATOR
Intervention: Internal tocodynamometry
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: IUP
Number of subjects: 503
Study: 24988413

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate, high-fat (LC) diet (6-7 MJ/day; 35% protein, 4% carbohydrate, 61% fat)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate, high-fat (LC) diet
Number of subjects: 76

Group type: COMPARATOR
Intervention: Isocaloric high-carbohydrate, low-fat (HC) diet
Number of subjects: 76
Study: 22639013

Group type: EXPERIMENTAL
Intervention: 1.8 g of sodium
Number of subjects: 360000

Group type: EXPERIMENTAL
Intervention: 3.8 g of sodium
Number of subjects: 360000

Group type: COMPARATOR
Intervention: Sodium intake <4.5 g/day
Number of subjects: 360000

Group type: COMPARATOR
Intervention: Sodium intake >4.5 g/day
Number of subjects: 360000

Group type: COMPARATOR
Intervention: Sodium intake 2.5 to 6.0 grams/day
Number of subjects: 360000
Study: 19224430

Group type: EXPERIMENTAL
Intervention: PIO (45 mg) + placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: SIMVA (40 mg) + placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: PIO + SIMVA
Number of subjects: 125

Group type: COMPARATOR
Intervention: All treatment arms (PIO, SIMVA, PIO + SIMVA)
Number of subjects: 125

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 125
Study: 17568648

Group type: EXPERIMENTAL
Intervention: Transient VEP in response to isoluminant chromatic (L-M) sinewave gratings
Number of subjects: 49
Study: 15209970

Group type: EXPERIMENTAL
Intervention: Quantitative thermal sensory testing using Medoc sensory analyzer with copper rods preheated to 40, 43, 46, and 49 degrees C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pressure testing with a 1.25-inch diameter commercially available pressure transducer gauge
Number of subjects: 40
Study: 11602545

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation during hospital stay
Number of subjects: 17944

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 17944
Study: 10206302

Group type: EXPERIMENTAL
Intervention: Comparative genomic hybridization (CGH)
Number of subjects: 23
Study: 7614520

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg (titrated up to 40 mg) once in the evening
Number of subjects: 168

Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 168
Study: 2146369

Group type: EXPERIMENTAL
Intervention: Isoniazid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 361026

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31676650

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 8324

Group type: EXPERIMENTAL
Intervention: Sedentary Behaviour (SB)
Number of subjects: 8324

Group type: EXPERIMENTAL
Intervention: Cognitive tasks and accelerometers
Number of subjects: 8324

Group type: EXPERIMENTAL
Intervention: Event-related potentials using electroencephalogram
Number of subjects: 8324
Study: 28332191

Group type: EXPERIMENTAL
Intervention: Combined Er:YAG (160 mJ/pulse, 10 Hz) and Nd:YAG laser (100 mJ/pulse, 20 Hz) therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 25
Study: 24990956

Group type: EXPERIMENTAL
Intervention: Recovery Management Intervention (RMI)
Number of subjects: 100
Study: 24142853

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 109

Group type: COMPARATOR
Intervention: Carperitide
Number of subjects: 109
Study: 21444654

Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (20 sessions in the first 4 weeks of inpatient therapy)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 48
Study: 18319446

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Newsletter (Control)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Not applicable (Contemplation stage at baseline)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Not applicable (Participation barriers)
Number of subjects: 139
Study: 17542202

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (Elmex sensitive toothpaste, 1400 ppm F) plus fluoride mouthrinse (Elmex sensitive rinse containing 250 ppm F) used twice a day.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo mouthrinse without fluoride used twice a day with the same fluoride toothpaste.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluoride toothpaste and mouthrinse (Group A) vs. placebo mouthrinse (Group B).
Number of subjects: 100
Study: 15509203

Group type: EXPERIMENTAL
Intervention: 20 mg sublingual sildenafil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11827307

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assays (ELISA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: ELISA
Number of subjects: 64

Group type: COMPARATOR
Intervention: IgE determination
Number of subjects: 64

Group type: COMPARATOR
Intervention: ELISA alone or in combination with SPT
Number of subjects: 64
Study: 9606248

Group type: EXPERIMENTAL
Intervention: Single telephone call reminder 1 day before the appointment
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Successful telephone call reminder
Number of subjects: 703

Group type: COMPARATOR
Intervention: Control group (no reminder)
Number of subjects: 703
Study: 9290020

Group type: EXPERIMENTAL
Intervention: Sex hormone receptors
Number of subjects: 240
Study: 1764956

Group type: EXPERIMENTAL
Intervention: Fendiline (75 mg twice daily)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg twice daily)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both medications
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fendiline
Number of subjects: 79
Study: 6805031

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg) + Naloxone (0.4 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ethanol (0.75 g/kg) + Saline
Number of subjects: 39
Study: 30943275

Group type: EXPERIMENTAL
Intervention: Azilsartan (20 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Telmisartan (40 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both azilsartan and telmisartan
Number of subjects: 33
Study: 28412954

Group type: EXPERIMENTAL
Intervention: Quality Improvement Campaign (Project JOINTS)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Non-campaign states
Number of subjects: 188
Study: 26453668

Group type: EXPERIMENTAL
Intervention: Healthcare Assistant (HCA)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Nurse
Number of subjects: 602
Study: 23942133

Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral etoricoxib
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral gabapentin
Number of subjects: 120